CD274 and neutropenia: ✓ PD-L1-positive tumors treated with atezolizumab plus nab-paclitaxel increased the OS and prolonged PFS✓ PD-L1-negative tumors treated with atezolizumab plus nab-paclitaxel did not have any improvement✓ Most common adverse event was neutropenia